Exact Mass: 319.091
Exact Mass Matches: 319.091
Found 65 metabolites which its exact mass value is equals to given mass value 319.091,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
ci no 52015
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes V - Various > V04 - Diagnostic agents > V04C - Other diagnostic agents > V04CG - Tests for gastric secretion COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ibandronate
Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures. M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
2-(3,4-dihydro-2-methoxy-4-oxoquinazolinyl)-1H-indole-3-carboxaldehyde|orirenierine B
Ibandronate
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
(r)-phenyl-(toluene-4-sulfonylamino)-acetic acid methyl ester
methyl 3-[(2,4-dimethylphenyl)sulfonylamino]benzoate
METHYL 2-(4-METHYLPHENYLSULFONAMIDO)-2-PHENYLACETATE
(R)-2-(4-Methylphenylsulfonamido)-3-phenylpropanoicacid
1-Azulenesulfonic acid, 3,8-dimethyl-5-(1-methylethyl)-, sodium salt, hydrate (2:2:1)
2-[2-(4-morpholin-4-ylanilino)-1,3-thiazol-4-yl]acetic acid
N-(2,3-Dihydro-2-oxo-1H-benzimidazol-5-yl)-3-hydroxy-2-naphthalenecarboxamide
4-(6-METHOXY-2-NAPHTHYL)-6-(TRIFLUOROMETHYL)PYRIMIDIN-2-AMINE
Ro 19-4603
(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE (2R,3R)-2,3-DIHYDROXYSUCCINATE
N-[5-Acetyl-2-(benzyloxy)phenyl]methanesulfonamide
(R)-ethyl 2-(1-(benzyloxycarbonyl)ethyl)thiazole-5-carboxylate
[(1R)-1-(benzyloxycarbonylamino)-2-phenyl-ethyl]phosphinic acid
2-[benzyl-(4-methylphenyl)sulfonyl-amino]acetic acid
2-([(4-Methylphenyl)sulfonyl]amino)-3-phenylpropanoic acid
6,11-Dioxo-12-naphtho[2,3-b]indolizinecarboxylic acid ethyl ester
ibandronic acid
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
